A Case of Anterior Migration of Fragmented Dexamethasone Intravitreal Implant

Purpose: To report a case of fragmentation and anterior migration occurred after dexamethasone intravitreal implant (Ozurdex, Allergan, Irvine, CA, USA) injection in a branch retinal vein occlusion patient. Case summary: A 66-year-old male was referred for blurred vision. He received cataract surgery in 1986 and was diagnosed with central retinal vein obstruction in 2011 in the right eye. For treatment of macular edema, dexamethasone intravitreal implant was performed in the right eye. One week after implantation, a fragment of the dexamethasone implant migrated to the anterior chamber with corneal edema and surgical removal was performed immediately. One day after removal, the remaining fragmented implant migrated to the anterior chamber and corneal edema still existed. The fragmented implant was removed with anterior chamber irrigation. After removal, corneal edema improved and visual acuity was recovered. Conclusions: Anterior migrated dexamethasone implant could induce corneal complications, such as corneal edema and corneal decompensation and might lower the corneal endothelial cell even if immediately removed. We report a case of corneal edema, which was induced by anterior migration of a fragmented dexamethasone implant and recovered with immediate surgical removal. J Korean Ophthalmol Soc 2016;57(4):667-671

[1]  Wayne Smith,et al.  Prevalence and Associations of Retinal Vein Occlusion in Australia , 2017 .

[2]  Y. Dang,et al.  Comparison of dexamethasone intravitreal implant and intravitreal triamcinolone acetonide for the treatment of pseudophakic cystoid macular edema in diabetic patients , 2014, Drug design, development and therapy.

[3]  S. Yeh,et al.  Sustained-Release Corticosteroid Options , 2014, Journal of ophthalmology.

[4]  M. Elman,et al.  Dexamethasone implant anterior chamber migration: risk factors, complications, and management strategies. , 2014, Ophthalmology.

[5]  S. Schaal,et al.  Management of Anterior Chamber Dislocation of Dexamethasone Implant , 2013, Ocular immunology and inflammation.

[6]  Kishan Govind,et al.  Late migration of dexamethasone implant into anterior chamber. , 2012, Archives of ophthalmology.

[7]  R. Gallego-Pinazo,et al.  Anterior chamber migration of dexametasone intravitreal implant (Ozurdex®) , 2012, Graefe's Archive for Clinical and Experimental Ophthalmology.

[8]  Sarah Gray,et al.  Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. , 2010, Ophthalmology.

[9]  M. Blumenkranz,et al.  Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. , 2010, Ophthalmology.

[10]  George A. Williams,et al.  Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. , 2007, Archives of ophthalmology.

[11]  J. Dissel,et al.  Effect of intravitreal dexamethasone on vitreous vancomycin concentrations in patients with suspected postoperative bacterial endophthalmitis , 2005, Graefe's Archive for Clinical and Experimental Ophthalmology.

[12]  P. Aspinall,et al.  Safety and efficacy of a dexamethasone anterior segment drug delivery system in patients after phacoemulsification , 2004, Journal of cataract and refractive surgery.

[13]  P. Mitchell,et al.  Prevalence and associations of retinal vein occlusion in Australia. The Blue Mountains Eye Study. , 1996, Archives of ophthalmology.

[14]  Ditte J. Hess,et al.  A randomized clinical trial of early panretinal photocoagulation for ischemic central vein occlusion. The Central Vein Occlusion Study Group N report. , 1995, Ophthalmology.

[15]  M. Zimmerman,et al.  Incidence of various types of retinal vein occlusion and their recurrence and demographic characteristics. , 1994, American journal of ophthalmology.